GlassScriptPhysician profile
Paul J Mason
NPI 1598762320
$5,113.20
in general payments reported to CMS, 2019-2025
29 companies · $3,404 in 2025
The $3,404 reported for 2025 was more than what 78% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $115 · 2021: $345 · 2022: $384 · 2023: $189 · 2024: $290 · 2025: $3,404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,740 · Food and Beverage: $1,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,740.44 |
| Food and Beverage | $1,142.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $4,189.96 | 2019-2025 | Real Intelligence, Journey II, Legion Revision |
| Stryker Corporation | $71.53 | 2021 | |
| Novo Nordisk INC | $61.35 | 2022-2024 | Wegovy, Ozempic, Rybelsus |
| Medtronic, INC. | $60.86 | 2023-2024 | Absorbatack |
| Pacira Pharmaceuticals Incorporated | $58.50 | 2022-2025 | Zilretta, Iovera, Exparel |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.52 | 2023-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $48.99 | 2024 | Voquezna |
| Ermi LLC | $40.51 | 2021 | |
| Pacira Therapeutics, INC. | $38.29 | 2020-2021 | |
| Amgen INC. | $38.15 | 2022-2024 | Otezla, Repatha |
| Alk-Abello, INC | $37.22 | 2023 | Grastek, Odactra, Ragwitek |
| Exact Sciences Corporation | $36.12 | 2023-2024 | Cologuard Collection Kit |
| Solventum Corporation | $34.17 | 2025 | Prevena |
| Avanos Medical | $33.40 | 2019-2021 | |
| Heraeus Medical, LLC. | $31.35 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $30.71 | 2019-2022 | |
| Vertex Pharmaceuticals Incorporated | $27.15 | 2025 | |
| Sumitomo Pharma America, INC. | $22.59 | 2024 | Gemtesa |
| Anika Therapeutics, INC. | $22.19 | 2021 | |
| Edwards Lifesciences Corporation | $21.59 | 2025 | Sapien 3 Ultra Resilia |
| Integra Lifesciences Corporation | $20.19 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Kowa Pharmaceuticals America, INC. | $19.49 | 2022 | |
| Insulet Corporation | $18.66 | 2024 | Omnipod |
| Abbott Laboratories | $18.18 | 2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $16.77 | 2024 | Arexvy, Trelegy Ellipta |
| Dexcom, INC. | $16.16 | 2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $15.72 | 2023 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Otsuka America Pharmaceutical, INC. | $14.33 | 2024 | Rexulti |
| Zimmer Biomet Holdings, INC. | $12.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.